Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This study is designed to determine the number of donor lymphocytes that can be given to
recipients of haploidentical stem cell transplants after depletion of recipient-reactive T
lymphocytes by ex-vivo treatment with a fixed dose of RFT5-dgA immunotoxin, and will result
in a rate of Grade III/IV GVHD of < / = 25%, to analyze immune reconstitution in these
patients, and to measure their overall and disease free survival, at 100 days and at 1 year.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
Collaborator:
University of Texas, Southwestern Medical Center at Dallas